Condition Skull Base Care

Craniopharyngioma

A rare, noncancerous brain tumor that develops near the pituitary gland and can affect vision, hormones, growth, and hypothalamic function.

Medically reviewed by Yaron A. Moshel, MD, PhD Last reviewed July 28, 2026 9 min read

Quick Answer

A craniopharyngioma is a rare, noncancerous brain tumor that develops near the pituitary gland, optic nerves, and hypothalamus. Although it does not spread to other parts of the body, its location can affect vision, hormone function, growth, and other important functions. There are two distinct types — adamantinomatous and papillary — with different molecular features, age patterns, and increasingly different treatment options. Treatment may include surgery, radiation, targeted drug therapy for selected tumors with a specific mutation, or a combination, with the goal of controlling the tumor while protecting vision, hormone function, and the hypothalamus.

Key Takeaways

Craniopharyngiomas are rare, noncancerous tumors that develop near the pituitary gland, optic nerves, and hypothalamus.
They occur in both children and adults, with age patterns that differ by tumor type.
There are two distinct types: adamantinomatous and papillary craniopharyngioma.
Nearly all papillary craniopharyngiomas carry a BRAF V600E mutation, creating a potential target for drug therapy.
Treatment may include surgery, focused radiation, targeted therapy for selected BRAF-mutated tumors, or a combination.
Protecting the hypothalamus, vision, and hormone function can be more important than removing every visible piece of tumor.
Long-term follow-up includes imaging, vision monitoring, and management of pituitary and hypothalamic hormone effects.

At a Glance

What it is	A rare, noncancerous tumor near the pituitary gland, optic nerves, and hypothalamus
Types	Adamantinomatous and papillary craniopharyngioma — two distinct WHO grade 1 tumor types
Who it affects	Children and adults; adamantinomatous tumors occur in both, while papillary tumors occur almost exclusively in adults
Key molecular markers	CTNNB1 pathway alterations in adamantinomatous tumors; BRAF V600E in nearly all papillary tumors
Common effects	Vision changes, hormone problems, headaches, hypothalamic symptoms, and growth changes in children
Diagnosis	MRI, vision testing, hormone evaluation, and molecular testing of tumor tissue when appropriate
Treatment	Surgery, focused radiation, targeted therapy for selected BRAF-mutated tumors, or a combination
Long-term care	Ongoing imaging, vision monitoring, and hormone management

Types of Craniopharyngioma

Craniopharyngioma was once considered a single tumor with two appearances under the microscope. It is now understood as two distinct tumor types, each with different molecular features, age patterns, imaging characteristics, and treatment implications.

Adamantinomatous Craniopharyngioma

The more common type, occurring in both children and adults. These tumors are often partly solid and partly cystic, may contain calcium deposits visible on CT, and are associated with alterations in the CTNNB1 pathway. They can adhere closely to the pituitary stalk and hypothalamus, which can make complete removal risky.

Papillary Craniopharyngioma

Seen almost exclusively in adults. Nearly all carry a BRAF V600E mutation. They are usually more solid and less likely to calcify. The BRAF mutation is especially important because it can make targeted drug therapy an option for selected patients.

Why the distinction matters: Imaging may suggest the tumor type, but tissue confirms the diagnosis. When a papillary tumor is suspected, identifying a BRAF mutation can influence the treatment sequence and, in selected cases, may reduce the extent of surgery needed.

Signs & Symptoms

Because a craniopharyngioma grows where the optic nerves, pituitary gland, and hypothalamus meet, symptoms commonly involve vision, hormone function, and pressure on nearby brain structures.

Vision

Loss of side or peripheral vision is common as the tumor presses on the optic nerves. Vision changes may develop gradually and can be difficult to notice at first.

Hormones & Growth

Symptoms may include fatigue, weight changes, excessive thirst and urination, and changes in sexual or reproductive function. In children, slowed growth or delayed puberty may be an early clue.

Pressure & Hypothalamic Effects

Headache, nausea, or drowsiness can occur if fluid flow is blocked. Hypothalamic involvement may also affect appetite, weight regulation, body temperature, sleep, thirst, memory, or behavior.

Symptoms usually develop gradually over months. In children, poor growth may be one of the earliest signs; in adults, progressive vision loss or hormone-related symptoms more often lead to diagnosis.

Common Signs & Symptoms

Loss of side or peripheral vision
Headaches, nausea, or drowsiness
Excessive thirst and frequent urination
Fatigue or unexplained weight changes
Slowed growth or delayed puberty in children

When to Seek Care Promptly

Rapidly worsening or sudden vision loss
Severe headache with vomiting or drowsiness
New confusion or marked change in alertness
Rapidly worsening balance or neurological symptoms
Severe dehydration or inability to maintain fluid balance

Diagnosis

Diagnosis combines imaging with vision and hormone testing. MRI with contrast shows the tumor’s relationship to the optic nerves, pituitary gland, hypothalamus, and surrounding structures. CT can be particularly useful for identifying calcification, which is common in adamantinomatous tumors.

Imaging

MRI defines the tumor and its relationship to critical structures. The imaging pattern can sometimes suggest whether a tumor is adamantinomatous or papillary before tissue is obtained.

Vision & Hormones

Formal visual field testing measures peripheral vision, while a comprehensive endocrine evaluation identifies pituitary and hypothalamic hormone effects before treatment.

Tumor Tissue & Molecular Testing

Tissue confirms the diagnosis and can identify molecular changes such as BRAF V600E in papillary craniopharyngioma. That result may open a targeted treatment option.

When imaging and age strongly suggest a papillary tumor, the team may consider obtaining tissue before a larger operation so BRAF testing can help guide the treatment sequence. Whether testing occurs before or after definitive surgery is individualized.

Treatment

The goal of treatment is durable tumor control while protecting vision, hormone function, and the hypothalamus. Because the hypothalamus helps regulate appetite, weight, body temperature, sleep, thirst, and other functions, removing every visible piece of tumor is not always the safest goal.

Protecting the hypothalamus matters. When tumor is firmly attached to the hypothalamus, deliberately leaving a small amount behind and treating the residual tumor with focused radiation may offer a better balance between tumor control and long-term quality of life than aggressive removal.

Surgery

Many craniopharyngiomas can be removed using an endoscopic endonasal approach performed through the nostrils, avoiding an external incision and minimizing brain retraction. This approach reaches many tumors from below and can provide a direct view beneath the optic nerves. Tumors extending in certain directions may instead require a craniotomy, and cystic tumors may benefit from drainage or other cyst-directed procedures.

Targeted Therapy for BRAF-Mutated Tumors

For papillary craniopharyngiomas with a BRAF V600E mutation, targeted medication that blocks the BRAF/MEK pathway can produce substantial tumor shrinkage in selected patients. This may be used before or after surgery depending on the individual case and is coordinated with medical oncology.

Focused Radiation

When complete removal would place critical structures at unnecessary risk, focused radiation may be used to control residual tumor. Treatment is carefully planned around the optic pathways and hypothalamus. In children, the potential long-term effects of radiation on the developing brain are an important part of treatment planning.

Hormone replacement is frequently needed when the pituitary gland or stalk has been affected, and for some patients it is lifelong. Follow-up may include management of water balance, thyroid and adrenal function, growth and puberty in children, weight, vision, and other hypothalamic effects.

Craniopharyngiomas are not cancerous, and long-term survival is generally favorable. The major challenge is preserving function and quality of life while maintaining tumor control. Because these tumors can recur years later, long-term imaging and endocrine follow-up remain important.

Multidisciplinary Skull Base Care

Why the Team Matters

Craniopharyngioma treatment requires decisions about how much tumor to remove, when protecting the hypothalamus should take priority, and when radiation or targeted therapy may offer a better balance. Care may involve skull base neurosurgery, ENT, endocrinology, ophthalmology, neuroradiology, radiation oncology, medical oncology, and pediatric specialists when appropriate.

Recognized Skull Base Team

Atlantic Brain and Spine’s Skull Base Surgery Center has been designated a Multidisciplinary Team of Distinction by the North American Skull Base Society, recognizing an established multidisciplinary approach to skull base care.

The Diagnosis-to-Treatment Pathway

1. Evaluation

History and neurological examination identify vision, hormone, growth, and hypothalamic symptoms.

2. Imaging

MRI defines the tumor and its relationship to the optic nerves, pituitary gland, hypothalamus, and surrounding structures; CT may help identify calcification.

3. Vision and hormone testing

Formal visual fields and endocrine testing establish how the tumor is affecting vision and pituitary function.

4. Define the tumor type

Imaging and tissue analysis distinguish adamantinomatous from papillary craniopharyngioma; BRAF testing is especially important when papillary tumor is suspected.

5. Treatment planning

The team weighs surgery, focused radiation, targeted therapy for selected BRAF-mutated tumors, and the importance of protecting the hypothalamus and optic pathways.

6. Treatment

Surgery may be endoscopic endonasal or, for selected tumors, transcranial; residual disease may be treated with focused radiation and BRAF-mutated papillary tumors may be candidates for targeted therapy.

7. Long-term follow-up

MRI, vision testing, endocrine care, and monitoring of hypothalamic effects continue for years because recurrence and long-term hormone needs are possible.

Frequently Asked Questions

No. Adamantinomatous and papillary craniopharyngiomas are WHO grade 1 tumors and do not spread through the body like cancer. They can still cause serious problems because of their location near the optic nerves, pituitary gland, and hypothalamus.

Long-term survival is generally favorable. The major challenges are controlling the tumor while preserving vision, hormone function, and hypothalamic functions such as appetite, weight regulation, and sleep.

Some tumors can be completely removed safely. In other cases, intentionally leaving tumor that is tightly attached to critical structures and treating the remainder with radiation may provide a better balance of tumor control and long-term function.

They are distinct tumor types with different molecular features and age patterns. Adamantinomatous tumors occur in children and adults and are associated with CTNNB1 pathway alterations. Papillary tumors occur almost exclusively in adults and nearly always carry a BRAF V600E mutation.

Selected papillary craniopharyngiomas with a BRAF V600E mutation may respond to targeted medication that blocks the BRAF/MEK pathway. Molecular testing of tumor tissue determines whether this option applies.

Many craniopharyngiomas can be treated through an endoscopic endonasal approach through the nostrils. Tumors with certain patterns of extension may require a craniotomy. The approach is chosen based on the tumor’s anatomy and relationship to critical structures.

Often, yes. The tumor and its treatment can affect pituitary or hypothalamic function. Some patients need long-term or lifelong hormone replacement, along with ongoing endocrine monitoring.

Yes. Recurrence can occur years after treatment, even after successful initial therapy. Long-term MRI and clinical follow-up are therefore important.

Our skull base team is ready to help you understand your options.

Your care is provided by Atlantic Brain and Spine’s experienced skull base specialists, working closely with endocrinology, ophthalmology, and other specialists as needed.